Performance of the CellaVision® DM96 system for detecting red blood cell morphologic abnormalities

Christopher L. Horn¹,², Adnan Mansoor², Brenda Wood², Heather Nelson², Diane Higa², Lik Hang Lee¹,², Christopher Naugler¹,²

¹Department of Pathology and Laboratory Medicine, University of Calgary, ²Calgary Laboratory Services, Calgary, AB T2L 2K8, Canada

E-mail: *Dr. Christopher Naugler - christopher.naugler@cls.ab.ca
*Corresponding author

INTRODUCTION

Microscopic examination of peripheral blood films is time-consuming, labor intensive, requires highly trained staff and remains subject to significant statistical variance.[¹] Recent advances in laboratory medicine have allowed for automated devices, like the CellaVision® DM96 (CCS; CellaVision, Lund, Sweden), to screen for specific cell abnormalities at a much more efficient rate than without automation.[²‑⁷] Previous evaluations of these types of systems have shown good correlations with the manual differentiation of normal cells.[⁴,⁸,⁹]

Automated red blood cell (RBC) analysis and screening therefore presents clinical laboratories with the potential to process large sample volumes, while ensuring a high accuracy rate in diagnosis. In particular, routine...
identification of the absence or presence of abnormal morphological features in RBC can be an important diagnostic tool for many hematologic diseases. For example, the presence of acanthocytes in blood smears may indicate hemolytic anemia of severe liver disease. However, microscopic analysis is still needed when abnormal cells are present because automated analyzers offer limited morphological information for RBC’s. Some institutions may choose to “autoverify” the results from the Cellavision® DM96 into their Laboratory Information System. However, at Calgary Laboratory Services (CLS) the RBC morphologic abnormalities identified by the system are sent for medical laboratory technologist (MLT) or pathologist review. Therefore at CLS, the Cellavision® DM96 is primarily used as a screening tool for RBC morphologic abnormalities.

In this paper, we assessed the ability of the Cellavision® DM96 in identifying RBC morphologic abnormalities.

METHODS

Cellavision® DM96

The Cellavision® DM96 is an automated system for in vitro diagnostic practice. The system scans a user-defined portion of a microscopy slide and automatically locates and presents images of cells on blood smears. A peripheral blood application is specified for differential count of white blood cells, classification of RBC morphology and platelet estimation. The Cellavision® DM96 system overlays the digitized image with a grid to facilitate accurate cell counting. The operator recognizes and verifie the recommended classification of all cells according to types specified in a preexisting database. For RBC morphology, the Cellavision® DM96 system scans one zone equivalent to eight fields using a ×100 objective. The Cellavision® DM96 system is outfitted with four flag levels to discriminate between six morphological abnormalities of size and color of RBCs including hypochromasia, polychromasia, microcytosis, macrocytosis, anisocytosis and poikilocytosis, and has the ability to characterize several more, many of which are included in this study. Only the RBC abnormalities that are routinely screened at CLS were examined.

Selection Criteria

Peripheral blood smears performed as part of routine medical care were collected from five hematology labs in Calgary, Alberta, Canada. Four of the centers are acute care facilities: Foothills Medical Center (50 smears), Peter Lougheed Centre (50 smears), the Rockyview General Hospital (35 smears) and the Alberta Children’s Hospital (37 smears). The fifth lab is the Diagnostic and Scientific Center (40 smears), which collects and analyses samples from the Calgary community and surrounding towns.

The selection criteria for the study identified “abnormal” RBC morphological samples at each site. These samples were identified by randomly selecting “abnormally” screened RBC morphology samples by the initial screening device, the Coulter LH 780 analyzer. The analyzer identifies nonspecific RBC abnormalities such as low/high hemoglobin or mean corpuscular volume. These nonspecific abnormalities trigger the analyzer to automatically create a peripheral smear on a glass slide. These slides were then chosen manually for specific RBC abnormalities. Abnormal samples identified with RBC morphological defects were collected until a preselected amount of samples was met. Once this amount was reached the slides were screened by the Cellavision® DM96 and also by the MLTs at each site.

Smears and Stains

The blood samples from each site were collected in 5 ml ethylenediaminetetraacetic acid tubes. Slide smears of the abnormal slides were made using an automatic Coulter LH 780 slide maker and then stained with Wright-Giemsa by the Coulter LH slide stainer. Each slide was selected for only one specific abnormality. As a result, each slide acted in effect as a negative control for every other abnormality.

Differential Counts

Each site performed manual differentiation using standard microscopic techniques on each of the slides. For standard RBC morphology identification, the smears were evaluated, as per CLS hematology department guidelines, by using a ×100 objective lens scanning 10 separate fields [Table 1]. These standards were based on hematology reference materials and then established using International Society for Laboratory Hematology guidelines for suggested action following automated complete blood count differential analysis. Each slide was scored at each individual site by two experienced MLTs. In cases of observer disagreement, a third MLT served as a tie-breaker.

All of the sites had experienced MLTs (25+ year’s experience) evaluate the slides. The results were reported as either present or absent for 15 different RBC morphological abnormalities: Acanthocytes, basophilic stippling, burr cells, Howell–Jolly bodies, ovalocytes, Pappenheimer bodies, polychromasia, RBC agglutination,
rouleaux, schistocytes, sickle cells, spherocytes, stomatocytes, target cells and tear drop cells.

The same slides were analyzed by the Cellavision® DM96 system. Each slide was scored and data was collected using the same criteria as the manual differential method where RBC morphology abnormalities were reported as present or absent. The classification of any of the RBC abnormalities studied is a manual addition from the instrument screen and is not automatic. The Cellavision® DM96 and glass slide classifications were then compared in truth tables and sensitivities and specificities calculated. A representative digitized field from the Cellavision® DM96 system is shown in Figure 1.

RESULTS

Results from the classification into normal and abnormal were sorted into the categories in Table 2. In regards to sensitivity, we observed a wide range of results in identifying RBC morphological abnormalities. For some RBC abnormalities, such as stomatocytes and sickle cells, there was a 100% sensitivity rate. However, for RBC agglutination and burr cells, there were low sensitivity rates of 33% and 47%, respectively. The other abnormalities ranged in sensitivity from 56% to 84%, respectively.

In regards to specificity, we found more consistent results among the RBC abnormalities. The range of specificity was from 84% for schistocytes to 99.5% for both sickle Cells and stomatocytes with the other RBC abnormalities within these two values. The majority of the RBC abnormalities were in the upper 90%.

DISCUSSION

We observed generally very good specificities but variable sensitivities when the Cellavision® DM96 system was used to classify RBC morphologic abnormalities when compared to traditional glass slide microscopy. There is only very limited existing literature addressing this question, and reported results have varied widely. One prior study compared a different analytical system, the Diffmaster Octavia, with the Cellavision® DM96. The results showed impressive sensitivity and specificity results.[6] However, the two different systems were compared only to each other and not to a proper reference method such as the industry gold standard manual differential. Another study showed that when...
direct microscopy was used as the reference method against, which the results of the CellaVision® DM96 were compared, with all discrepant results included in the analysis, the specificity was 82–93% and sensitivity was 25–91%, – which was similar to the results of this study.[11] Finally, another study reported that blood cell and platelet morphology was judged to be adequate; however it was not specific for RBC morphological abnormalities.[12]

There are several possible limitations in this study. First, the MLTs participating at each laboratory involved in the study only analyzed the slides from their individual sites. As a result, although the slides were presented in a blinded fashion to the MLTs, there is a large probability that the same technologist manually read the slide and reclassified the CellaVision® DM96 results. This may have enhanced the correlation between the automated and manual classification methods.

In addition, the selection of peripheral blood smears for this study is not random as slides only with abnormalities were selected. The percentage of abnormal smears is low in routine hematopathology practice and a random sample would evaluate very low numbers of abnormal smears. Additionally, the testing of normal blood samples has already been performed and the results have already shown the CellaVision® DM96 to be reliable and accurate.[6]

One interesting observation, corroborated by our study, was that RBC agglutination sensitivity has tested poorly in other CellaVision® DM96 validation studies. Billard et al., has previously shown decreased sensitivity in platelet aggregates/"thrombocytic agglutinates" and RBC agglutination. [12] This study, and the Billard et al. study, may indicate a possible limitation in sensitivity for RBC agglutination in the CellaVision® DM96.

**CONCLUSIONS**

This study shows that the CellaVision® DM96 has acceptable specificity, but lacks consistency for sensitivity. A future test featuring sensitivity of RBC agglutination, and other low scoring RBC morphologic abnormalities, combined with a larger number of samples may be warranted to confirm these results.

**REFERENCES**

1. Rümke CL. Imprecision of ratio‑derived differential leukocyte counts. Blood Cells 1985;11:311–4, 315.
2. Hilborne LH, Wenger NS, Oye RK. Physician performance of laboratory tests in self-service facilities. Residents' perceptions and performance. JAMA 1990;264:382–6.
3. Cornet E, Perol JP, Troussard X. Performance evaluation and relevance of the CellaVision DM96 system in routine analysis and in patients with malignant hematological diseases. Int J Lab Hematol 2008;30:536–42.
4. Kratz A, Bengtsson HL, Casey JF, Keefe JM, Beatrice GH, Grzybek DY, et al. Performance evaluation of the CellaVision DM96 system: WBC differentials by automated digital image analysis supported by an artificial neural network. Am J Clin Pathol 2005;124:770–81.
5. Yu H, Ok CY, Hesse A, Nordell P, Connor D, Spolsted E, et al. Evaluation of an automated digital imaging system, Nextslide Digital Review Network, for examination of peripheral blood smears. Arch Pathol Lab Med 2012;136:660–7.
6. Ceelie H, Dinkelaar RB, van Gelder W. Examination of peripheral blood films using automated microscopy; evaluation of Diffmaster Octavia and CellaVision DM96. J Clin Pathol 2007;60:72–9.
7. Horiuchi Y, Tabe Y, Idei M, Bengtsson HL, Ishii K, Hori T, et al. The use of CellaVision competency software for external quality assessment and continuing professional development. J Clin Pathol 2011;64:610–7.
8. Gao Y, Mansoor A, Wood B, Nelson H, Higa D, Naugler C. Platelet count estimation using the CellaVision DM96 system. J Pathol Inform 2013;4:16.
9. Lee LH, Mansoor A, Wood B, Nelson H, Higa D, Naugler C. Performance of CellaVision DM96 in leukocyte classification. J Pathol Inform. 2013;4:14.
10. de Alarcon PA, Albers WH. Acanthocytosis, in Medscape Reference: Drugs, Diseases and Procedures; 2011.
11. Briggs C, Longair I, Slavik M, Thwaite K, Mills R, Thavaraja V, et al. Can automated blood film analysis replace the manual differential? An evaluation of the CellaVision DM96 automated image analysis system. Int J Lab Hematol 2009;31:48–60.
12. Billard M, Lainey E, Armoogum P, Alberti C, Fenneteau O, Da Costa L. Evaluation of the CellaVision DM automated microscope in pediatrics. Int J Lab Hematol 2010;32:530–8.
13. CellaVision, CellaVision® DM96 User’s Manual 3.1. Lund, Sweden: CellaVision AB; 2003–2010.
14. Calgary Laboratory Services. Differential and related procedures: Definition and grading for erythrocyte morphology. In: Hematology Procedure Manual. Calgary Laboratory Services; 2012.
15. Gulati G, Caro J. Red cell morphology compared with corresponding automated red cell indices. In: Blood Cells: An Atlas of Morphology. Singapore: American Society for Clinical Pathology; 2007. p. 208.
16. Barnes PW, McFadden SL, Machin SJ, Simson E. International Consensus Group for Hematology. The International Consensus Group for Hematology Review: Suggested criteria for action following automated CBC and WBC differential analysis. Lab Hematol 2005;11:83–90.